1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014

Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014’, provides an overview of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Overview 7
Pipeline Products for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis 8
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics under Development by Companies 9
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Products under Development by Companies 12
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Companies Involved in Therapeutics Development 13
Astellas Pharma Inc. 13
Merck and Co., Inc. 14
Novartis AG 15
Sumitomo Dainippon Pharma Co., Ltd. 16
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
amrubicin hydrochloride - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
buparlisib hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
enfortumab vedotin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
pembrolizumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
SNX-5422 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Recent Pipeline Updates 40
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables

Number of Products under Development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer), H2 2014 7
Number of Products under Development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Astellas Pharma Inc., H2 2014 13
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck and Co., Inc., H2 2014 14
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Novartis AG, H2 2014 15
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Recent Pipeline Updates, H2 2014 40
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects, H2 2014 49

List of Figures

Number of Products under Development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer), H2 2014 7
Number of Products under Development for Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Targets, H2 2014 18
Number of Products by Stage and Top 10 Targets, H2 2014 18
Number of Products by Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Top 10 Routes of Administration, H2 2014 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 22
Number of Products by Top 10 Molecule Types, H2 2014 24
Number of Products by Stage and Top 10 Molecule Types, H2 2014 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Cancer
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.